title: The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors.
abstract: OBJECTIVE
  The role of thrombophilia in the etiology of retinal vein occlusion (rVO) has not been adequately clarified. The aim of this study was to examine the prevalence of thrombophilia among RVO patients with and without systemic risk factors and among patients younger and older than 50 years.
  
  
  METHODS
  Prospective case-control study.
  
  
  METHODS
  One hundred and twenty one patients with RVO, including 92 with acquired risk factors (hypertension, hyperlipidemia, and diabetes mellitus) and 29 without these factors. The control group included 60 persons matched for age, sex, and risk factors.
  
  
  METHODS
  All participants were screened for Leiden mutation (FV Leiden), hyperprothrombinemia (20210 G/A mutation) and deficiency of protein C, S, and antithrombin.
  
  
  RESULTS
  The prevalence of FV Leiden was significantly higher among RVO patients without risk factors (24.1%) than among controls without risk factors (0%; p = 0.034) and among RVO patients with acquired disorders (4.3%; p = 0.001). No significant differences were found in the prevalence of the other investigated thrombophilic factors. In all, 37.9% patients without acquired risk factors were positive for at least 1 thrombophilic factor compared with 7.6% RVO patients with acquired risk factors (p < 0.001) and 8.3% of the controls (p < 0.001). There was no significant difference in the prevalence of thrombophilic disorders among RVO patients according to age.
  
  
  CONCLUSIONS
  FV Leiden is significantly more frequent among RVO patients without acquired risk factors. Thrombophilia plays a much more important role in the pathogenesis of RVO in patients without acquired risk factors. Screening for thrombophilia is thus indicated only for patients in whom these factors have been excluded.
authors.affiliation: Department of Ophthalmology, University of Leipzig, Germany.
authors.forename: Matus
authors.initials: M
authors.lastname: Rehak
authors.forename: Vera
authors.initials: V
authors.lastname: Krcova
authors.forename: Ludek
authors.initials: L
authors.lastname: Slavik
authors.forename: Evzen
authors.initials: E
authors.lastname: Fric
authors.forename: Katerina
authors.initials: K
authors.lastname: Langova
authors.forename: Jana
authors.initials: J
authors.lastname: Ulehlova
authors.forename: Jiri
authors.initials: J
authors.lastname: Rehak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000991:Antithrombins / Q000032:analysis; D016022:Case-Control Studies; D003920:Diabetes Mellitus / Q000209:etiology; D005165:Factor V / Q000235:genetics; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology; D006973:Hypertension / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011486:Protein C / Q000032:analysis; D017293:Protein S / Q000032:analysis; D012170:Retinal Vein Occlusion / Q000097:blood / Q000209:etiology / Q000503:physiopathology*; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications / Q000503:physiopathology*; D055815:Young Adult
chemical_list: D000991:Antithrombins; D011486:Protein C; D017293:Protein S; C095381:factor V Leiden; D005165:Factor V